Download New Combination Approaches to Enhance Rituximab-based Lymphoma Therapies Ebook PDF

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies
A Book

by Anonim

  • Publisher : Academic Press
  • Release : 2020-11-01
  • Pages : 250
  • ISBN : 0128167378
  • Language : En, Es, Fr & De
GET BOOK

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Resistance to Targeted Therapies in Lymphomas

Resistance to Targeted Therapies in Lymphomas
A Book

by Ana C. Xavier,Mitchell S. Cairo

  • Publisher : Springer Nature
  • Release : 2019-09-13
  • Pages : 210
  • ISBN : 3030244245
  • Language : En, Es, Fr & De
GET BOOK

Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.

The Lymphoid Neoplasms 3ed

The Lymphoid Neoplasms 3ed
A Book

by Ian Magrath

  • Publisher : CRC Press
  • Release : 2010-07-30
  • Pages : 1689
  • ISBN : 1444113224
  • Language : En, Es, Fr & De
GET BOOK

This comprehensive and authoritative reference covers all aspects of the group of disorders collectively known as the lymphoid neoplasms. The reader is taken through a description of its normal cellular origins and the molecular genetic abnormalities that can lead to this group of conditions, a section of the book that has been considerably strengthened for this third edition, to the environmental factors that may be relevant to disease development, and, finally, to the pragmatic aspects of disease management. The authors synthesise for the reader apsects of current knowledge and likely future developments, and direct them to the appropriate resources should they wish to pursue particular avenues of scientific or literature research.

Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy

Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
A Book

by Patrik Andersson,Christian Ostheimer

  • Publisher : Frontiers Media SA
  • Release : 2019-12-27
  • Pages : 329
  • ISBN : 2889631613
  • Language : En, Es, Fr & De
GET BOOK

The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.

Perry's The Chemotherapy Source Book

Perry's The Chemotherapy Source Book
A Book

by Michael C. Perry,Donald C. Doll,Carl E. Freter

  • Publisher : Lippincott Williams & Wilkins
  • Release : 2012-07-30
  • Pages : 848
  • ISBN : 1469803437
  • Language : En, Es, Fr & De
GET BOOK

Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

Lymphoma: New Insights for the Healthcare Professional: 2012 Edition

Lymphoma: New Insights for the Healthcare Professional: 2012 Edition
A Book

by Anonim

  • Publisher : ScholarlyEditions
  • Release : 2012-12-10
  • Pages : 255
  • ISBN : 1464970351
  • Language : En, Es, Fr & De
GET BOOK

Lymphoma: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Lymphoma. The editors have built Lymphoma: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Lymphoma in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Lymphoma: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Lymphoma: New Insights for the Healthcare Professional: 2011 Edition

Lymphoma: New Insights for the Healthcare Professional: 2011 Edition
A Book

by Anonim

  • Publisher : ScholarlyEditions
  • Release : 2012-01-09
  • Pages : 229
  • ISBN : 1464900949
  • Language : En, Es, Fr & De
GET BOOK

Lymphoma: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Lymphoma. The editors have built Lymphoma: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Lymphoma in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Lymphoma: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Biotargets of Cancer in Current Clinical Practice

Biotargets of Cancer in Current Clinical Practice
A Book

by Mauro Bologna

  • Publisher : Springer Science & Business Media
  • Release : 2012-04-03
  • Pages : 564
  • ISBN : 1617796158
  • Language : En, Es, Fr & De
GET BOOK

Biotargets of Cancer in Current Clinical Practice presents an updated and reasoned review of the current status of knowledge concerning the major cancer types with a special focus on the current biomarkers, genes involved and the potential future targets of innovative therapies. The volume includes for each major cancer type, a comprehensive although concise discussion of epidemiology, affirmed and innovative biomarkers for diagnosis, and descriptions of the relevant genes for prognosis and (individualized) therapy through biotarget-specific new molecular treatments, with the latest information on the validation status of each novel biomarker. Individual chapters are dedicated to the major cancer types, plus a special chapter on metastasis. The present debate on patentability of genetic information applied to diagnostics and therapeutics of cancer is also discussed.

Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality

Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality

by Abhishek D Garg,Patrizia Agostinis

  • Publisher : Frontiers Media SA
  • Release : 2016-04-29
  • Pages : 329
  • ISBN : 2889198383
  • Language : En, Es, Fr & De
GET BOOK

Classically, anti-cancer therapies have always been applied with the primary aim of tumor debulking achieved through widespread induction of cancer cell death. While the role of host immune system is frequently considered as host protective in various (antigen-bearing) pathologies or infections yet in case of cancer overtime it was proposed that the host immune system either plays no role in therapeutic efficacy or plays a limited role that is therapeutically unemployable. The concept that the immune system is dispensable for the efficacy of anticancer therapies lingered on for a substantial amount of time; not only because evidence supporting the claim that anti-cancer immunity played a role were mainly contradictory, but also largely because it was considered acceptable (and sometimes still is) to test anticancer therapies in immunodeficient mice (i.e. SCID/athymic mice lacking adaptive immune system). This latter practice played a detrimental role in appreciating the role of anticancer immunity in cancer therapy. This scenario is epitomized by the fact that for a long time the very existence of cancer-associated antigens or cancer-associated ‘danger signaling’ remained controversial. However, over last several years this dogmatic view has been considerably modified. The existence of cancer-associated antigens and ‘danger signaling’ has been proven to be incontrovertible. These developments have together paved way for the establishment of the attractive concept of “immunogenic cell death” (ICD). It has been established that a restricted class of chemotherapeutics/targeted therapeutics, radiotherapy, photodynamic therapy and certain oncolytic viruses can induce a form of cancer cell death called ICD which is accompanied by spatiotemporally defined emission of danger signals. These danger signals along with other factors help cancer cells undergoing ICD to activate host innate immune cells, which in turn activate T cell-based immunity that helps eradicate live (or residual) surviving cancer cells. The emergence of ICD has been marred by some controversy. ICD has been criticized to be either experimental model or setting-specific or mostly a concept based on rodent studies that may have very limited implications for clinical application. However, in recent times it has emerged (through mainly retrospective or prognostic studies) that ICD can work in various human clinical settings hinting towards clinical applicability of ICD. However a widespread consensus on this issue is still transitional. In the current Research Topic we aimed to organize and intensify a discussion that strives to bring together the academic and clinical research community in order to provide a background to the current state-of-the-art in ICD associated bench-side research and to initiate fruitful discussions on present and future prospects of ICD translating towards the clinical, bedside reality.

Developing Costimulatory Molecules for Immunotherapy of Diseases

Developing Costimulatory Molecules for Immunotherapy of Diseases
A Book

by Manzoor Ahmad Mir

  • Publisher : Academic Press
  • Release : 2015-05-25
  • Pages : 322
  • ISBN : 0128026758
  • Language : En, Es, Fr & De
GET BOOK

Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases

Yonsei Medical Journal

Yonsei Medical Journal
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2007
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Lymphoma: Pathology, Diagnosis and Treatment

Lymphoma: Pathology, Diagnosis and Treatment
A Book

by Robert Marcus,John W. Sweetenham,Michael E. Williams

  • Publisher : Cambridge University Press
  • Release : 2007-06-21
  • Pages : 277
  • ISBN : 9780521865449
  • Language : En, Es, Fr & De
GET BOOK

Places the major advances which have occurred in the area of lymphoma into the context of daily clinical practice.

Treatment of Cancer

Treatment of Cancer
A Book

by Pat Price,Karol Sikora

  • Publisher : CRC Press
  • Release : 2020-11-24
  • Pages : 614
  • ISBN : 0429651643
  • Language : En, Es, Fr & De
GET BOOK

Treatment of Cancer is a multi-author work and comprehensive guide on modern cancer treatment that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Much information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.

Cancer Immunology

Cancer Immunology
Cancer Immunotherapy for Organ-Specific Tumors

by Nima Rezaei

  • Publisher : Springer Nature
  • Release : 2021-01-13
  • Pages : 581
  • ISBN : 3030579492
  • Language : En, Es, Fr & De
GET BOOK

This book explains the immunology of organ-specific malignancies and discusses novel immunotherapy strategies for their treatment. Since the first, very successful edition of the book was published in 2015, a number of entirely new chapters have been included. The range of cancers considered has accordingly been extended, with coverage of the latest immunotherapy approaches for cancers in different organs. In addition, the original chapters have been updated to document the latest advances in immunotherapy for pediatric solid tumors, hematologic malignancies, gastrointestinal tumors, bone tumors, central nervous tumors, lung cancer, genitourinary tract tumors, and breast cancer, among others. The book is published as part of the three-volume Springer series Cancer Immunology, which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Other volumes in the series address the translational medicine context and bench to bedside immunotherapy. Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors will be of special value to clinical immunologists, hematologists, and oncologists.

Sherlock's Diseases of the Liver and Biliary System

Sherlock's Diseases of the Liver and Biliary System
A Book

by James S. Dooley,Anna S. F. Lok,Guadalupe Garcia-Tsao,Massimo Pinzani

  • Publisher : John Wiley & Sons
  • Release : 2018-06-08
  • Pages : 832
  • ISBN : 1119237564
  • Language : En, Es, Fr & De
GET BOOK

A new, fully updated edition of the world’s most famous book on liver diseases—with updating of all areas and inclusion of new specific topics, by internationally renowned specialists This brand new edition of the classic book on hepatology provides a concise, clearly presented and well-structured review across the whole spectrum of hepatobiliary diseases by some of the world’s leading hepatologists and hepatobiliary specialists. Where many other hepatology textbooks provide detailed accounts of basic science and clinical management, Sherlock's Diseases of the Liver and Biliary System, 13th Edition takes a different approach. Concentrating on the clinical decisions to be taken and the relevant supporting data, it is written and edited to maintain Sheila Sherlock's unique approach, in particular the clarity and layout of the text, and the explanatory figures and tables. The book is thus concise, highly accessible, and generously illustrated with over 700 attractive color figures. There is a pithy approach to each disease based both on evidence and on the authors’ experience, the hallmark of this book. Based on these elements, the 12th edition was awarded first prize in the 2012 British Medical Association Book Awards in the Internal Medicine category. Sherlock's Diseases of the Liver and Biliary System begins by introducing the anatomy and function of the liver to readers, continuing then with in-depth coverage of liver biopsy techniques and interpretation, and fibrogenesis and its assessment. There are then chapters on all aspects of liver and biliary disease including acute liver failure, cirrhosis, portal hypertension, hepatic encephalopathy, ascites, hepatitis B and C, alcohol and the liver, non-alcoholic fatty liver disease, drug related liver reactions, cholestatic, autoimmune and genetic liver diseases, benign and malignant tumours and not least liver transplantation. There are also chapters on the liver in pregnancy, in the neonate, infancy and childhood, in systemic diseases and in infections. This new edition also features four new individual chapters focusing on coagulation, non-invasive assessment of fibrosis and cirrhosis; vascular diseases of the liver and portal vein thrombosis, and nutrition in liver disease. Digital downloads of the figures from this edition are offered on a companion website. Internationally recognized and loved, world-renowned hepatology book, first published in 1955 Takes a one-of-a-kind, clinical approach maintaining Sheila Sherlock’s clarity and legacy of presentation Full colour throughout with 700 illustrative figures Wide faculty of international contributors Sherlock's Diseases of the Liver and Biliary System, 13th Edition is an ideal primer in hepatology for students and trainees in hepatology and gastroenterology, and a valuable resource for all specialist gastroenterologists and hepatologists, paediatricians, pathologists, radiologists, general physicians and specialist nurses.

Clinical Radiation Oncology

Clinical Radiation Oncology
A Book

by Leonard L. Gunderson,Joel E. Tepper

  • Publisher : Elsevier Health Sciences
  • Release : 2007
  • Pages : 1827
  • ISBN : 0443068402
  • Language : En, Es, Fr & De
GET BOOK

First Prize winner, Oncology Book Category, British Medical Association 2012 Medical Book Competition Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities. Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons. Broaden your understanding of the basic biology of the disease processes. Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches. Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques. Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors -many of whom are new to this edition - affiliated with institutions across North America and internationally Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more! Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy. Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens. Understand and comply with the latest staging guidelines. Drs. Gunderson and Tepper give you quick access to all the clinical tools you need to master the newest techniques and modalities in radiation oncology.

Clinical Radiation Oncology E-Book

Clinical Radiation Oncology E-Book
A Book

by Leonard L. Gunderson,Joel E. Tepper

  • Publisher : Elsevier Health Sciences
  • Release : 2011-09-16
  • Pages : 1660
  • ISBN : 1455726036
  • Language : En, Es, Fr & De
GET BOOK

With thorough updates throughout, Clinical Radiation Oncology provides the most comprehensive, authoritative, and up-to-date information available for treating patients with cancer. From a multidisciplinary perspective, this new edition, edited by Drs. Leonard L. Gunderson and Joel E. Tepper, examines the therapeutic management of specific disease sites based on both single-modality and combined-modality approaches - providing you with the well-rounded, cutting-edge guidance you need to offer the most effective treatments. A consistent chapter format, full-color design, and access to the full text at www.expertconsult.com make reference fast and easy. It is an ideal resource for mastering the latest, most effective techniques and modalities! Deepen your knowledge with a comprehensive, clinical approach to the scientific foundations of radiation oncology and general oncology as well as state-of-the-art techniques and modalities. Implement a multidisciplinary, "team care" approach to providing intricate treatment plans for patients, often in conjunction with medical oncologists, and surgeons. Broaden your understanding of the basic biology of the disease processes. Examine the therapeutic management of specific disease sites based on single-modality and combined-modality approaches. Quickly and easily find critical information thanks to an easily accessible, full-color design with over 800 color figures that clearly depict treatment techniques. Get broad multimodality perspectives and unique insights from a diverse team of respected editors and contributors –many of whom are new to this edition – affiliated with institutions across North America and internationally Access the fully searchable text anywhere, anytime at www.expertconsult.com, along with references, additional images and tables, video clips and more! Stay current with comprehensive updates throughout that include a new chapter on survivorship issues, and additional video clips on treatments such as prostate and penile cancer brachytherapy. Improve outcomes by providing the most effective treatment for each patient with expanded coverage of new modalities and treatment regimens. Understand and comply with the latest staging guidelines.

Journal of the National Cancer Institute

Journal of the National Cancer Institute
JNCI

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2002-05
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Dry Mouth, The Malevolent Symptom

Dry Mouth, The Malevolent Symptom
A Clinical Guide

by Leo M. Sreebny,Arjan Vissink

  • Publisher : John Wiley & Sons
  • Release : 2010-02-25
  • Pages : 280
  • ISBN : 9780813820972
  • Language : En, Es, Fr & De
GET BOOK

Xerostomia, more commonly called dry mouth, affects anestimated 20 percent of adults worldwide and can severelydiminish one’s quality of life. Dry Mouth, theMalevolent Symptom: A Clinical Guide relies on evidence-basedresearch to provide an introductory primer on oral dryness and themodalities available to treat it. The book describes thevaried etiology of the disease, but emphasizes clinicalprotocols and step-by-step procedures for diagnosis and treatmentplanning. Dry Mouth is a user-friendly manual guiding cliniciansthrough identifying and managing this common condition. Causesincluding radiotherapy, chemotherapy, systemic diseases,polypharmacy, and the natural progression of aging are discussed inconjunction with the clinical symptoms and signs associated witheach one. Multiple avenues for treatment are presented,highlighting salivary stimulation and supplementation techniques,pharmacologic aids, and critically required oral therapy. Althoughintended primarily for the professionals that treat those affectedby xerostomia, Dry Mouth may also be of interest tosufferers of this condition.

The Second Life of Natural Killer (NK) Cells

The Second Life of Natural Killer (NK) Cells
A Book

by Chiara Romagnani,Joseph C. Sun,Marco Colonna

  • Publisher : Frontiers Media SA
  • Release : 2018-07-16
  • Pages : 118
  • ISBN : 2889455467
  • Language : En, Es, Fr & De
GET BOOK

Natural Killer (NK) cells are innate lymphocytes, now recognized as members of a larger family of “Innate lymphoid cells” (ILCs). Both murine and human NK cells are well characterized effector cells with cytotoxic as well as cytokine production ability which mainly react in response to microbial and cell stress stimuli, thus playing a central role in the defense against pathogen infection, in tumor surveillance and in regulating immune homeostasis. Despite these established concepts, our understanding of the complexity of NK cells, also in view of their developmental and functional relationship with other ILC subsets, is only recently emerging. This Research Topic highlights the recent advances in NK cell (and ILC) research in human and mouse from basic research to clinical applications.